Summary of Product Characteristics for Pharmaceutical Products

1. Name of the medicinal product: NEXILEV KIT

2. Qualitative and quantitative composition

1. Esomeprazole

Each Enteric coated tablet contains Esomeprazole Magnesium Trihydrate equivalent to Esomeprazole 40mg

<u>Excipients with known effects</u> Each Esomeprazole 40mg Enteric coated tablet contains Lactose

<u>2. Levofloxacin Tablet</u> Each film coated tablet contains Levofloxacin Hemihydrate equivalent to Levofloxacin 500mg

Excipients with known effects Each Levofloxacin 500mg film coated tablet contains Isopropyl alcohol

<u>3. Amoxicillin Tablet</u> Each film coated tablet contains Amoxicillin Trihydrate equivalent to Amoxicillin 1000mg

<u>Excipients with known effects</u> Each Amoxicillin 1000mg Tablet contains Isopropyl Alcohol.

For a full list of excipients, see section 6.1.

3. Pharmaceutical form

<u>Amoxicillin Tablet USP 500 mg</u> Brown coloured elongated biconvex film coated tablets breakline on one side and plain on another side

<u>Levofloxacin Tablet USP 500 mg</u> Orange colored oblong shaped slightly biconvex tablets.

<u>Esomeprazole Tablet 40 mg</u> Yellow coloured, circular shaped slightly biconvex film coated tablets.

4. Clinical particulars

4.1 Therapeutic indications

NEXILEV KIT is indicated in the eradication of H. pylori in active chronic gastritis, duodenal and gastric ulcers.

4.2 Posology and method of administration

Adult Patient:

NEXILEV KIT contains 7 kits to be taken in 7 days.

Each one-day kit contains a morning kit and an evening kit.

Morning kit contains 1 tablet of Esomeprazole 40mg and 2 tablets of Amoxicillin 500mg and the evening kit contains 1 tablet of Levofloxacin and 2 tablets of Amoxicillin.

The recommended therapy is for seven days and may be extended as per the Physicians advice.

Pediatric and Adolescent: Since this product has not been studied in the adolescent and pediatric population this product is not recommended in this age group.

4.3 Contraindications

 A history of allergic reaction to any of the penicillin"s and infections caused by penicillinase producing organism are contraindicated.
Levofloxacin tablets must not be used:

- in patients hypersensitive to levofloxacin, or other quinolones or any of the excipients listed in section 6.1
- in patients with epilepsy,
- in patients with history of tendon disorders related to fluoroquinolone administration,
- in children or growing adolescents,
- during pregnancy,
- in breast-feeding women.

3. Hypersensitivity to the active substance, to substituted benzimidazoles or to any of the excipients listed in section 6.1. Esomeprazole should not be used concomitantly with nelfinavir and atazanavir.

4.4 Special warnings and precautions for use

Before initiating therapy with NEXILEV KIT, carefully inquire from the patient concerning hypersensitivity to penicillinS cephalosporin and other allergens. Serious and occasionally fatal hypersensitivit reactions (anaphylactic) have been reported in patients on penicillin therapy.

When prescribing Esomeprazole for eradication of Helicobacter pylori, possible drug interactions for all components in the triple therapy should be considered. Caution should be taken when using fluroquinolones, including levofloxacin, in patients with known risk factors for prolongation of the QT interval such as, for example:

- congenital long QT syndrome

- concomitant use of drugs that are known to prolong the QT interval (e.g. Class IA and III

antiarrhythmics, tricyclic antidepressants, macrolides, antipsychotics)

- uncorrected electrolyte imbalance (e.g. hypokalaemia, hypomagnesaemia)

- cardiac disease (e.g. heart failure, myocardial infarction,bradycardia) Elderly patients and women may be more sensitive to QTc-prolonging medications. Therefore, cautionshould be taken when using fluoroquinolones, including levofloxacin, in these populations

4.5 Interaction with other medicinal products and other forms of interaction

Effects of Esomeprazole on the pharmacokinetics of other drugs

Protease inhibitors

Esomeprazole has been reported to interact with some protease inhibitors. The clinical importance and the mechanisms behind these reported interactions are not always known. Increased gastric pH during omeprazole treatment may change the absorption of the protease inhibitors. Other possible interaction mechanisms are via inhibition of CYP2C19.

For atazanavir and nelfinavir, decreased serum levels have been reported when given together with omeprazole and concomitant administration is not recommended.

<u>Methotrexate</u>

When given together with PPIs, methotrexate levels have been reported to increase in some patients. In high-dose methotrexate administration a temporary withdrawal of Esomeprazole may need to be considered.

<u>Tacrolimus</u>

Concomitant administration of Esomeprazole has been reported to increase the serum levels of tacrolimus. A reinforced monitoring of tacrolimus concentrations as well as renal function (creatinine clearance) should be performed, and dosage of tacrolimus adjusted if needed.

Medicinal products with pH dependent absorption

Gastric acid suppression during treatment with Esomeprazole and other PPIs might decrease or increase the absorption of medicinal products with a gastric pH dependent absorption. As with other medicinal products that decrease intragastric acidity, the absorption of medicinal products such as ketoconazole, itraconazole and erlotinib can decrease and the absorption of digoxin can increase during treatment with Esomeprazole.

Medicinal products metabolised by CYP2C19

Esomeprazole inhibits CYP2C19, the major Esomeprazolemetabolising enzyme. Thus, when Esomeprazole is combined with drugs metabolised by CYP2C19, such as diazepam, citalopram, imipramine, clomipramine, phenytoin etc., the plasma concentrations of these drugs may be increased and a dose reduction could be needed. This should be considered especially when prescribing Esomeprazole for on-demand therapy.

<u>Diazepam</u>

Concomitant administration of 30 mg Esomeprazole resulted in a 45% decrease in clearance of the CYP2C19 substrate diazepam.

Phenytoin

Concomitant administration of 40 mg Esomeprazole resulted in a 13% increase in trough plasma levels of phenytoin in epileptic patients. It is recommended to monitor the plasma concentrations of phenytoin when treatment with Esomeprazole is introduced or withdrawn.

<u>Warfarin</u>

Concomitant administration of 40 mg Esomeprazole to warfarin-treated patients in a clinical trial showed that coagulation times were within the accepted range. However, post-marketing, a few isolated cases of elevated INR of clinical significance have been reported during concomitant treatment. Monitoring is recommended when initiating and ending concomitant Esomeprazole treatment during treatment with warfarin or other coumarine derivatives.

Effect of other medicinal products on levofloxacin

Iron salts, zinc salts, magnesium- or aluminium-containing antacid, didanosines

Levofloxacin absorption is significantly reduced when iron salts, or magnesium- or aluminium-containing antacids, or didanosine (only didanosine formulations with aluminium or magnesium containing buffering agents) are administered concomitantly with Levofloxacin tablets. Concurrent administration of fluoroquinolones with multivitamins containing zinc appears to reduce their oral absorption. It is recommended that preparations containing divalent or trivalent cations such as iron salts, zinc salts or magnesium- or aluminium-containing antacids, didanosine (only didanosine formulations with aluminium or magnesium containing buffering agents) should not be taken 2 hours before or after Levofloxacin tablet administration (see section 4.2). Calcium salts have a minimal effect on the oral absorption of levofloxacin.

Sucralfate

The bioavailability of Levofloxacin tablets is significantly reduced when administered together with sucralfate. If the patient is to receive both sucralfate and levofloxacin, it is best to administer sucralfate 2 hours after the levofloxacin administration (see section 4.2).

<u>Theophylline, fenbufen or similar non-steroidal anti-inflammatory drugs</u> No pharmacokinetic interactions of levofloxacin were found with theophylline in a clinical study. However a pronounced lowering of the cerebral seizure threshold may occur when quinolones are given concurrently with theophylline, nonsteroidal anti-inflammatory drugs, or other agents which lower the seizure threshold. Levofloxacin concentrations were about 13% higher in the presence of fenbufen than when administered alone.

Probenecid and cimetidine

Probenecid and cimetidine had a statistically significant effect on the elimination of levofloxacin. The renal clearance of levofloxacin was reduced by cimetidine (24%) and probenecid (34%). This is because both drugs are capable of blocking the renal tubular secretion of levofloxacin. However, at the tested doses in the study, the statistically significant kinetic differences are unlikely to be of clinical relevance. Caution should be exercised when levofloxacin is coadministered with drugs that affect the tubular renal secretion such as probenecid and cimetidine, especially in renal impaired patients.

When administered concurrently, the following Drugs may interact with Amoxicillin:

1. Allopurinol may increase possibilities of hypersensitivity reactions.

2. Chloramphenicol, tetracyclines, Sulphonamides and macrolide antibiotics may interfere with bactericidal effects of penicillins.

3. Oral contraceptives may be less effective and increase break through bleeding may occur.

4. Probenecid may decrease renal tubular secretion of Amoxicillin resulting in its increased blood levels and or Amoxicillin toxicity.

4.6 Fertility, pregnancy, and lactation

Amoxicillin

Use in pregnancy: Animal studies with Amoxicillin have shown no teratogenic effects. The product has been in extensive clinical use since 1972 and its suitability in human pregnancy has been well documented in clinical studies. When antibiotic therapy is required during pregnancy, Amoxicillin may be considered appropriate when the potential benefits outweigh the potential risks associated with treatment.

Use in lactation: Amoxicillin may be given during lactation. With the exception of the risk of sensitization associated with the excretion of trace quantities of amoxicillin in breast milk, there are no known detrimental effects for the breast-fed infant.

Esomeprazole

Pregnancy

Clinical data on exposed pregnancies with Esomeprazole are insufficient. With the racemic mixture omeprazole data on a larger

number of exposed pregnancies from epidemiological studies indicate no malformative nor foetotoxic effect. Animal studies with Esomeprazole do not indicate direct or indirect harmful effects with respect to embryonal/foetal development. Animal studies with the racemic mixture do not indicate direct or indirect harmful effects with respect to pregnancy, parturition or postnatal development. Caution should be exercised when prescribing to pregnant women.

A moderate amount of data on pregnant women (between 300-1000 pregnancy outcomes) indicates no malformative or foeto/neonatal toxicity of Esomeprazole.

Breast-feeding

It is not known whether Esomeprazole is excreted in human breast milk. There is insufficient information on the effects of Esomeprazole in newborns/infants. Esomeprazole should not be used during breastfeeding.

Fertility

Animal studies with the racemic mixture omeprazole, given by oral administration do not indicate effects with respect to fertility.

Levofloxacin

<u>Pregnancy</u>

There are limited amount of data from the use of levofloxacin in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive toxicity (see section 5.3). However, in the absence of human data and due to that experimental data suggest a risk of damage by fluoroquinolones to the weight-bearing cartilage of the growing organism, levofloxacin must not be used in pregnant women (see section 4.2 and 5.3).

Breast-feeding

The product is contraindicated in breast-feeding women. There is insufficient information on the excretion of levofloxacin in human milk; however other fluoroquinolones are excreted in breast milk. In the absence of human data and due to the experimental data suggests risk of damage by fluoroquinolones to the weight-bearing cartilage of the growing organism, levofloxacin must not be used in breast-feeding women (see sections 4.3 and 5.3).

Fertility

Levofloxacin caused no impairment of fertility or reproductive performance in rats.

4.7 Effects on ability to drive and use machines.

Esomeprazole

Esomeprazole has minor influence on the ability to drive or use machines. Adverse reactions such as dizziness (uncommon) and blurred vision (rare) has been reported. If affected patients should not drive or use machines.

Levofloxacin

Some undesirable effects (e.g. dizziness/vertigo, drowsiness, visual disturbances) may impair the patient's ability to concentrate and react, and therefore may constitute a risk in situations where these abilities are of special importance (e.g. driving a car or operating machinery).

Amoxicillin

Adverse effects on the ability to drive or operate machinery have not been observed

4.8 Undesirable effects

Esomeprazole

System Organ Class	Frequency	Undesirable Effect
Blood and lymphatic	Rare	Leukopenia,
system disorders		thrombocytopenia
	Very rare	Agranulocytosis,
		pancytopenia
Immune system	Rare	Hypersensitivity reactions
disorders		e.g. fever, angioedema and
		anaphylactic reaction/shock
Metabolism and		Uncommon Peripheral
nutrition disorders		oedema
	Rare	Hyponatraemia
	Not known	• Hypomagnesaemia (see
		section 4.4); severe
		hypomagnesaemia can
		correlate with
		hypocalcaemia.
		Hypomagnesaemia may also
		be associated with
		hypokalaemia.
Psychiatric disorders	Uncommon	Insomnia
	Rare	Agitation, confusion,
		depression
	Very rare	Aggression, hallucinations
Nervous system	Common	Headache
disorders	Uncommon	Dizziness, paraesthesia,
		somnolence
	Rare	Taste disturbance
Eye disorders	Rare	Blurred vision
Ear and labyrinth	Uncommon	Vertigo
disorders		

Respiratory, thoracic and mediastinal disorders	Rare	Bronchospasm
Gastrointestinal disorders	Common	Abdominal pain, constipation, diarrhoea, flatulence, nausea/vomiting
	Uncommon Dry mouth	
	Rare	Stomatitis, gastrointestinal candidiasis
	Not known	Microscopic colitis
Hepatobiliary disorders	Uncommon	Increased liver enzymes
	Rare	Hepatitis with or without jaundice
	Very rare	Hepatic failure, encephalopathy in patients with preexisting liver disease
Skin and subcutaneous tissue disorders	Uncommon	Dermatitis, pruritus, rash, urticaria
	Rare	Alopecia, photosensitivity
	Very rare	Erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis (TEN)
Musculoskeletal and connective tissue disorders		Uncommon Fracture of the hip, wrist or spine (see section 4.4)
	Rare	Arthralgia, myalgia
	Very rare	Muscular weakness
Renal and urinary disorders	Very rare	Interstitial nephritis; in some patients renal failure has been reported concomitantly.
Reproductive system and breast disorders	Very rare	Gynaecomastia
General disorders and administration site conditions	Rare	Malaise, increased sweating

Levofloxacin

System organ class	Common 21/100 to < 1/10)	21/1,000 to <1/100)	Rare 21/10,000 to < 1/1,000)	Not known (cannot be estimated from available data)
Infections and infestations		Fungal infection including Candidia infection Pathogen resistance		Genital moniliasis
Reproductiv e System				Vaginitis

lymphatic system disordersEosinophiliaenia Pancytopenia Metabolism and nutrition disordersEosinophiliaenia Pancytopenia Metabolism ad nutrition disordersEosinophiliaenia Pancytopenia Metabolism ad nutrition disordersEosinophiliaenia Pancytopenia Metabolism ad nutrition disordersEosinophiliaenia Pancytopenia Metabolism ad nutrition disordersEosinophiliaenia Pancytopenia Metabolism ad nutrition disordersAnorexiaAngioedma Hypoglycaemia a particularly in diabetic section 4.4)AnorexiaHaemolytic anaphylactic shock (see section 4.4)Psychiatric disordersInsomnia Anxiety Confusional stateAnxiety Confusional state NervousnessPsychotic reaction (with e.g. paranoia) Depression Agitation Agitation sucide attempt (see section 4.4)Psychotic disorders with self- endangering behaviour including sucidel attempt (see section 4.4) Peripheral sensory section 4.4) ParasethesiaNervous disordersMetadache DizzinessSomnolence Tremor DysgeusiaConvulsions section 4.3 and 4.4) ereinpheralia curopathy (see gerasethesiaPeripheral sensory motor neuropathy (see section 4.4) ParasethesiaEye disordersImage additional sensory motor neuropathy (see section 4.4)Image additional sensory motor neuropathy (see section 4.4) ParasethesiaEye disordersVertigoVisual disturbances Transient disordersIoss (see section 4.4)<	Blood and		Leukopenia	Thrombocytop	Agranulocytosi
System disordersDownsprink and NeutropeniaHaemolytic anaemia Anaphylactic shock?Immune system disordersAnaretia Anaphylactic ty (see section 4.4)Maphylactic shock?Metabolism and nutrition disordersAnorexiaHypoglycaemia a anorexiaAnorexia a particularly in diabetic patients (see section 4.4)Hypoglycaemia a a particularly in diabetic patients (see section 4.4)Psychiatric disordersInsomnia take Anxiety Confusional state NervousnessAnxiety Psychotic reaction (with e.g. hallucinations paranoia) Depression Agitation disordersPsychotic disordersNervous disordersHeadache DizzinessSomnolence Tremor DysgeusiaConvulsions section 4.3 and 4.4) ParasethesiaPeripheral sensory section 4.4) ParasethesiaNervous disordersHeadache DizzinessSomnolence Tremor DysgeusiaConvulsions section 4.3 and 4.4) ParasethesiaPeripheral sensory section 4.4) ParasethesiaPye disordersImage disordersVertigoVisual disordersJoss (see section 4.4)Eye disordersVertigoVisual disordersJoss (see section 4.4)Eye disordersVertigoTinnitusHearing loss Hearing	lymphatic		Eosinophilia	enia	8
System disordersInaction byte NeutropentiaInaction byte anaemiaImmune system disordersAngioedma HypersensitisAnaphylactici shock2Anaphylactici shock2Metabolism and nutrition disordersAnorexiaHypoglycaemi a a tion disordersHypoglycaemi a disordersPsychiatric disordersInsomniaAnxiety Confusional state NervousnessPsychotic reaction (with e.g. patients (see section 4.4)Psychotic reaction (with e.g. patients (see section 4.4)Psychiatric disordersInsomniaAnxiety Confusional state NervousnessPsychotic reaction (with e.g. patients (see section 4.4)Psychotic reaction (with e.g. patients (see section 4.4)Nervous system disordersHeadache DizzinessSomnolence Tremor DysgeusiaConvulsions (see section 4.3)Peripheral sensory section 4.4)Nervous system disordersHeadache DizzinessSomnolence Tremor DysgeusiaConvulsions (see section 4.4)Peripheral sensory motor neuropathy (see section 4.4)Peripheral sensory motor rescing and 4.4)Parosmia Dyskinesia Extrapyramida 1Synocope Benign intracranial hyperension HypoaesthesiaEye disordersVertigoVisual disturbances Transient vision such as blurred vision such as blurred tion disordersSomocope Hearing disorders	system		Loomophina	Pancytopenia	Haemolytic
ClisordersNetworkAnagioedmaAnaginationsystem disordersAngioedmaAnaphylactic shock?Anaphylactoid shock (see section 4.4)Metabolism and nutrition disordersAnorexiaHypeglycaemi a particularly in diabetic coma (see section 4.4)Psychiatric disordersInsomniaAnxiety Confusional state NervousnessPsychotic reaction (with e.g. hallucinations parancial) behaviour including suicidal Abnormal disordersPsychotic disordersPsychotic disordersNervous disordersHeadache DizzinessSomnolence Tremor DysgeusiaConvulsions (see section 4.4)Section 4.4) suicidal Abnormal including suicidal abnormal including suicidal abnormal including suicidal abnormal including section 4.4)Peripheral section 4.4)Nervous system disordersHeadache DizzinessSomnolence Tremor DysgeusiaConvulsions (see section 4.3) and 4.4) Peripheral and 4.4) Peripheral and 4.4)Peripheral and 4.4) Peripheral and 4.4) ParasethesiaEye disordersImage and and an anormia and and an anormia and and an anormia and 4.4)Synocope Benign intracranial hypogesthesiaEye disordersVertigoVisual disturbances Transient vision such as blurred vision (see section 4.4)Insertion and 4.4)Ear and LabyrinthVertigoTinnitusHearing loss Hearing image disturbances	diagndana			Nastronomia	
Immune system disordersAnaphylactic Metabolism and mutrition disordersAnaphylactic Metabolism and mutrition disordersAnorexiaAnaphylactic Hypersestici anorexiaAnaphylactic Mypersestici anorexiaAnaphylactic Mypersestici anorexiaAnaphylactic Mypersestici anorexiaAnaphylactic Mypersestici anorexiaAnaphylactic Mypersestici anorexiaAnaphylactic Mypersestici anorexiaAnaphylactic Mypersestici anorexiaAnaphylactic Mypersestici anorexiaAnaphylactic Mypersestici anorexiaAnaphylactic Mypersestici anorexiaAnaphylactic Mypersestici anorexiaAnaphylactic Mypersestici anorexiaAnaphylactic Mypersestici anorexiaAnaphylactic Mypersestici anorexiaAnaphylactic Mypersestici anorexiaAnaphylactic MypersesticiNervous system disordersHeadache 	disorders			Neutropenia	anaenna
system disordersHypestensitivi ty (see section 4.4)shock? ty (see section 4.4)Metabolism and nutrition disordersAnorexiaHyperstensitivi ty (see section 4.4)Hyperglycaemi a a particularly in taste NervousnessHyperstensitivi section 4.4)Hyperglycaemi a a particularly in taste hallucinations paranoia) behaviour behavio	Immune			Angioedma	Anaphylactic
disordersAnaphylactoid shock (see section 4.4)Anaphylactoid shock (see section 4.4)Metabolism and nutrition disordersAnorexiaHypoglycaemi a patients (see section 4.4)Hypoglycaemic coma (see section 4.4)Psychiatric disordersInsomniaAnxiety Confusional state NervousnessPsychotic reaction (with e.g. patients (see section 4.4)Psychotic reaction (with e.g. hallucinations uideation or suicidal abnormal ideation or suicidal Abnormal ideation or suicidal abnormal disordersPsychotic reaction (with e.g. patients (see section 4.4)Psychotic reaction (with e.g. section 4.4)Nervous system disordersHeadache DizzinessSomnolence Tremor DysgeusiaConvulsions (see section 4.3) and 4.4) reuropathy (see parasethesiaPeripheral sensory motor neuropathy (see section 4.4)Nervous system disordersHeadache DizzinessSomnolence Tremor DysgeusiaConvulsions section 4.3 and 4.4) reuropathy (see section 4.4)Nervous system disordersHeadache DizzinessSomnolence Tremor DysgeusiaConvulsions section 4.3 and 4.4) reuropathy (see section 4.4)Peripheral section 4.4)Somory motor and 4.4) parasethesiaSomoria disorders synocope Benign intracranial hypertension HypoasethesiaEye disordersVertigoVisual distrubances transientloss (see section 4.4)Exe disordersVertigoTinnitusHearing disorder	system			Hypersensitivi	shock?
Metabolism and nutrition disordersAnorexiaHypoglycaemia a particularly in diabetic section 4.4)shock (see section 4.4)Psychiatric disordersInsomniaAnxiety Confusional state NervousnessPsychotic reaction (with e.g. hallucinations partanoia) Depression diabeticPsychotic disorders with esction 4.4)Nervous system disordersInsomniaAnxiety Confusional state NervousnessPsychotic reaction (with e.g. hallucinations paranoia) Depression including Agitation Agitation section 4.4)Psychotic disorders with esction 4.4)Nervous system disordersHeadache DizzinessSomnolence Tremor DysgeusiaConvulsions section 4.4) and 4.4) neuropathy (see fearasethesiaPeripheral sensory section 4.4)Nervous system disordersHeadache DizzinessSomnolence Tremor DysgeusiaConvulsions section 4.3 and 4.4) reuropathy (see section 4.4)Peripheral sensory motor and 4.4) ParasethesiaEye disordersIntervous sucideIntervous section 4.4)Anorexia section 4.4)Eye disordersIntervous section 4.4)Intervous section 4.4)Eye disordersIntervous section sectionSomolence tremor tremorYeition (see section 4.4)Intervous section 4.4)Intervous section 4.4)Somoria section 4.4)Intervous section section (seeSomia Dyskinesia section 4.4)Intervous section section section section section	disorders			ty (see section	Anaphylactoid
Metabolism and nutrition disordersAnorexiaHypoglycaemi a aHypoglycaemic a particularly in diabetic patients (see section 4.4)Hypoglycaemic a aPsychiatric disordersInsomniaAnxiety Confusional statePsychotic reaction (with e.g. hallucinations , paranoia) Depression Agitation disordersPsychotic disorders with self- endangering behaviour including suicidal ideation or statePsychotic reaction (with e.g. hallucinations , paranoia) Depression Agitation dreams suicidal ideation or suicidal ideation or suicidal ideation or section 4.4)Nervous system disordersHeadache DizzinessSomnolence Tremor DysgeusiaConvulsions (see section 4.3 and 4.4) ParasethesiaPeripheral section 4.4) Peripheral section 4.4) Peripheral section 4.4)Nervous system disordersSomnolence Tremor DysgeusiaConvulsions (see section 4.3 and 4.4) ParasethesiaPeripheral section 4.4) Peripheral section 4.4) Peripheral section 4.4) Parosmia including transient vision such as blurred vision (see section 4.4)Eye disordersImage: Section 4.4)Image: Section 4.4)Eye disordersImage: Section 4.4)Image: Section 4.4)Ear and LabyrinthVertigoTinnitusHearing loss disordersVertigoTinnitusEar and LabyrinthVertigoTinnitusHearing loss disordersVertigoTinnitus				4.4)	shock (see
Metabolism and nutrition disordersAnorexiaHypoglycaemi a particularly in diabetic patients (see section 4.4)Hyperglycaemi a Hyperglycaemi a Hypoglycaemi Section 4.4)Psychatric disordersInsomnia Anxiety Confusional state Nervous system disordersAnxiety Psychotic reaction 4.4) Peripheral sensory section 4.4) ParasethesiaPsychotic reaction 4.4) sensory motor neuropathy (see section 4.4) ParasethesiaNervous system disordersHeadache DizzinessSomnolence Transient vision such as burred vision (see section 4.4)Peripheral sensory motor neuropathy (see sensory motor neuropathy (see Synocope Benign intracranial hypotesthesiaEye disordersVertigoVisual tisud uison (see section 4.4)Isos (see section 4.4)Ear and LabyrinhVertigoTinitusHearing loss Hearing<				,	section 4 4)
Metadonism and nutrition disordersAnorexiaInpregycaemin a particularly in diabetic patients (see section 4.4)Hypogycaemin coma (see section 4.4)Psychiatric disordersInsomniaAnxiety Confusional statePsychotic reaction (with e.g. hallucinations paranoia) Depression Agitation suicidal Abnormal disordersPsychotic disorders with self- nalducinations including suicidal ideation or suicidal disordersPsychotic disorders with self- self- suicidal ideation or suicidal ideation or suicidal Abnormal disardersPsychotic disordersNervous system disordersHeadache DizzinessSomnolence Tremor DysgeusiaConvulsions section 4.3 and 4.4) Peripheral section 4.4)Peripheral section 4.4) Peripheral section 4.4) Peripheral section 4.4)Nervous system disordersParasethesia a convulsionsese section 4.4) ParasethesiaA.4) Parosmia including anosmia Dyskinesia Extrapyramidal 1 disordersEye disordersImage: paranoi biordersImage: paranoi biorder AgeusiaImage: paranoi biorder AgeusiaEye disordersImage: paranoi biorder AgeusiaImage: paranoi biorder AgeusiaImage: paranoi biorder AgeusiaEye disordersImage: paranoi biorder AgeusiaImage: paranoi biorder AgeusiaImage: paranoi biorder AgeusiaEye disordersImage: paranoi biorderImage: paranoi biorderImage: paranoi biorder AgeusiaEye 	Matabaliana		Amonaria	I I am a glava a amai	Urm angless a angl
and nutrition disordersInsomniaAnxiety Anxiety Confusional state NervousnessPsychotic reaction (with e.g. paratoia) Depression Agitation Agitation Abnormal disedrersPsychotic disordersPsychotic disordersNervous system disordersHeadache DizzinessSomnolence Tremor DysgeusiaConvulsions section 4.4)Peripheral section 4.4)Nervous system disordersHeadache DizzinessSomnolence Tremor DysgeusiaConvulsions section 4.4)Peripheral section 4.4)Nervous system disordersHeadache DizzinessSomnolence Tremor DysgeusiaConvulsions section 4.4)Peripheral section 4.4)Nervous system disordersHeadache DizzinessSomnolence Tremor DysgeusiaConvulsions section 4.4)Peripheral section 4.4)Nervous system disordersHeadache DizzinessSomnolence Tremor DysgeusiaConvulsions section 4.4)Peripheral sensory motor neuropathy (see section 4.4)Nervous system disordersHeadache DizzinessSomolence Transient section 4.4)Somolence section 4.4)Nervous system disordersHeadache DizzinessSomolence Transient vision such as blurred vision (see section 4.4)Altipheral section 4.4)Eve disordersHeating Transient vision (see section 4.4)Somolence section 4.4)Eve disordersVertigoTinnitusHearing loss Hearing	Metabolisin		Anorexia	Hypoglycaeini	Hyperglycaeiii
nutrition disordersInsomniaAnxiety Anxiety Confusional state Nervousnessparticularly in diabetic patients (see section 4.4)Hypoglycaemic coma (see section 4.4)Psychiatric disordersInsomniaAnxiety Confusional state NervousnessPsychotic reaction (with e.g. hallucinations dreams NightmaresPsychotic disorders with self- endangering behaviour including suicidal dideation or suicidal Abnormal dreams suicidal Abnormal dreams suicidal section 4.4)Psychotic disordersPsychotic disordersNervous system disordersHeadache DizzinessSomnolence Tremor DysgeusiaConvulsions (see section 4.3 and 4.4) peripheral sensory section 4.4)Peripheral sensory section 4.4) ParasethesiaPye disordersImage: section 4.3 and 4.4) sensory motor neuropathy (see section 4.4)Anosmia possina including anosmia Dyskinesia Extrapyramidal l disordersSomolence tremor DysgeusiaConvulsions (see section 4.3 and 4.4) peripheral sensory motor neuropathy (see section 4.4)Eye disordersImage: section 4.4)Sisonders anosmia Dyskinesia Extrapyramidal intracranial <b< td=""><td>and</td><td></td><td></td><td>a</td><td>a</td></b<>	and			a	a
disordersInsomniaAnxiety Confusional state NervousnessPsychotic reaction (with e.g. hallucinations , paranoia) Depression Agitation Abnormal dreams suicidal ideation or section 4.4)Psychotic disorders with self- hallucinations neutolug agitation Agitation Abnormal dreams suicidal ideation or section 4.4)Nervous system disordersHeadache DizzinessSomnolence Tremor DysgeusiaConvulsions section 4.3 and 4.4) section 4.4)Peripheral sensory section 4.4) peripheral section 4.4)Nervous system disordersHeadache DizzinessSomnolence Tremor DysgeusiaConvulsions section 4.3 and 4.4) neuropathy (see ParasethesiaPeripheral sensory section 4.4) Peripheral sensory motor neuropathy (see section 4.4) Parosmia including anosmia 1 disordersEye disordersImage: Section 4 All AllVisual disordersloss (see section 4 4.4) parosmia including anosmia includingEye disordersImage: Section 4 AllVisual disordersloss (see section 4.4) errosmia intracranial hypertension HypoaesthesiaEye disordersImage: Section AllVisual disturbances section 4.4) errosmia intracranial hypertension HypoaesthesiaEyr disordersVertigoTinnitusHearing loss Hearing impaired	nutrition			particularly in	Hypoglycaemic
Psychiatric disordersInsomniaAnxiety Confusional state NervousnessPsychotic reaction (with e.g. hallucinations , paranoia) Depression suicidal Abnormal ideation or suicidal Abnormal ideation or section 4.4)Psychotic disentersNervous system disordersHeadache DizzinessSomnolence Tremor DysgeusiaConvulsions section 4.3 and 4.4) peuropathy (see parasethesiaPeripheral sensory motor neuropathy (see section 4.4)Nervous disordersHeadache DizzinessSomnolence Tremor DysgeusiaConvulsions section 4.3 and 4.4) peuropathy (see section 4.3 and 4.4) peropathy (see section 4.4)Peripheral sensory motor neuropathy (see section 4.4)Peripheral supprension HypoaesthesiaImage: Simple able able able able able able able ab	disorders			diabetic	coma (see
Psychiatric disordersInsomnia InsomniaAnxiety Confusional state NervousnessPsychotic reaction (with e.g. hallucinations perssion Agitation Abnormal dreams suicida Abnormal dreams suicide attempt (see section 4.4)Nervous system disordersHeadache DizzinessSomnolence Tremor DysgeusiaConvulsions (see section 4.3) and 4.4) neuropathy (see sensory section 4.4)Peripheral sensory section 4.4)Nervous system disordersHeadache DizzinessSomnolence Tremor DysgeusiaConvulsions (see section 4.3) and 4.4) neuropathy (see parasethesiaPeripheral sensory section 4.4)Nervous system disordersHeadache DizzinessSomnolence Tremor DysgeusiaConvulsions (see section 4.3) and 4.4) neuropathy (see sensory motor neuropathy (see sensory motor neuropathy (see sensory motor neuropathy (see sensory motor neuropathy sensoria including anosmia Dyskinesia Extrapyramida 1 disordersEye disordersVisual disordersIoss (see section 4.4)Ioss (see section 4.4)Eye disordersVertigoTinnitusHearing loss Hearing immaired				patients (see	section 4.4)
Psychiatric disordersInsomniaAnxiety Confusional state NervousnessPsychotic reaction (with e.g. hallucinations , paranoia) Depression adjatation Agitation Abnormal dreams NightmaresPsychotic disorders with self- hallucinations sucidal abnormal dreams section 4.4)Psychotic disordersPsychotic disordersNervous system disordersHeadache DizzinessSomnolence Tremor DysgeusiaConvulsions section 4.3 and 4.4) neuropathy (see ParasethesiaPeripheral sensory motor neuropathy (see section 4.3) and 4.4) ParasethesiaPeripheral sensory motor neuropathy (see section 4.4)Eye disordersImage: section 4.3 and 4.4) Parosemia includingImage: section 4.4) ParasethesiaPeripheral sensory motor neuropathy (see section 4.4)Eye disordersVisual disordersImage: section 4.4) Parosemia includingImage: section 4.4) Parosemia including anosmia Dyskinesia Extrapyramida l titracranial hypotesthesiaImage: section 4.4) Parosemia including anosmia Dyskinesia Extrapyramida l disordersEye disordersVertigoTinnitusHearing loss Hearing impaired				section 4.4)	,
Taylenatic disordersInsortinal insortinalTimetay restrict insortinalTigetable isorders with self- hallucinations paranoia) Depression Agitation dreams wicidal ideation or suicida ideation or suicidal ideation or suicidal ideation or suicidal ideation or suicidal ideation or suicidal ideation or suicidal ideation or section 4.4)Tigetable disordersDiscription disordersNervous system disordersHeadache DizzinessSomnolence Tremor DysgeusiaConvulsions (see section 4.3) and 4.4) neuropathy (see ParasethesiaPeripheral sensory section 4.4) Peripheral sensory motor neuropathy (see section 4.4) ParasethesiaEye disordersImage: section 4.4 bit ParasethesiaAnosmia including anosmia includingEye disordersImage: section A.4)Image: section A.4)Eye disordersImage: section A.4)Image: section A.4) <td>Psychiatric</td> <td>Insomnia</td> <td>Anviety</td> <td>Psychotic</td> <td>Psychotic</td>	Psychiatric	Insomnia	Anviety	Psychotic	Psychotic
Lisorder'sConnusional state NervousnessTeaction (wind) self- endangering bhallucinations , paranoia) Depression Agitation dreamsself- endangering bhaviour including suicidal attempt (see section 4.4)Nervous system disordersHeadache DizzinessSomnolence Tremor DysgeusiaConvulsions (see section 4.3) and 4.4) Peripheral sensory section 4.4)Serifyleral sensory section 4.4) Peripheral sensory motor neuropathy (see ses sensory section 4.4) ParasethesiaNervous disordersHeadache DizzinessSomnolence Tremor DysgeusiaConvulsions (see section 4.3) and 4.4) ParasethesiaSensory section 4.4) Peripheral sensory motor neuropathy (see section 4.4) ParasethesiaPeripheral sector pyskinesia Extrapyramida 1 disordersSomolence tremor typeSomolence tremor section 4.3 and 4.4) ParasethesiaPeripheral sensory motor neuropathy (see section 4.4) Parosmia including anosmia Dyskinesia Extrapyramida 1 disordersEye disordersVertigoVisual disturbances Transient vision such as blurred vision (see section 4.4)Ioss (see section 4.4)Ear and Labyrinth disordersVertigoTinnitusHearing loss Hearing imaired	digordorg	msomma	Confusional	ropotion (with	digordorg with
State Nervousnesse.g. hallucinations , paranoia) Depression Agitation dreams wicidal ideation or suicidal ideation or suicidal ideation or suicidal ideation or suicidal ideation or suicidal ideation or suicidal ideation or suicidal ideation or suicidal anormal dreams section 4.4)endagering behaviour including suicidal ideation or suicidal section 4.4)Nervous system disordersHeadache DizzinessSomnolence Tremor DysgeusiaConvulsions (see section 4.3 and 4.4) neuropathy (see ParasethesiaPeripheral sensory motor neuropathy (see ParasethesiaImage: section disordersImage: section disorder disordersSomnolence peripheral sensory motor neuropathy (see parasethesiaPeripheral sensory motor neuropathy (see parasethesiaImage: section disordersImage: section disorder disordersImage: section disorder disordersImage: section disorder disordersImage: section disordersImage: section disorder disordersImage: section disorder disordersImage: section disorder disordersImage: section disordersImage: section disorder disordersImage: section disorder disorder disorderImage: section disorder disorders <t< td=""><td>disorders</td><td></td><td>Comusional</td><td>reaction (with</td><td></td></t<>	disorders		Comusional	reaction (with	
Nervousnesshallucinationsendangering behaviour including suicidal Abnormal dreams Nightmaresendangering behaviour including suicidal attempt (see section 4.4)Nervous system disordersHeadache DizzinessSomnolence Tremor DysgeusiaConvulsions section 4.3 and 4.4) ParasethesiaPeripheral sensory motor neuropathy (see ParasethesiaNervous disordersHeadache DizzinessSomnolence Tremor DysgeusiaConvulsions section 4.3 and 4.4) Parasethesia4.4) ParasethesiaNervous disordersHeadache DizzinessSomnolence Tremor DysgeusiaSee section 4.3 and 4.4) Parasethesia4.4) Parosmia including including disordersPye disordersImage: Section 4.4,0 ParasethesiaA.4) ParasethesiaParasethesiaFye disordersImage: Section 4.4,0 ParasethesiaSomocope ParasethesiaSomocia ParasethesiaFye disordersImage: Section 4.4,0 ParasethesiaImage: Section 4.4,0 ParasethesiaA.4,1 Parosmia ParasethesiaFye disordersImage: Section 4.4,0 ParasethesiaImage: Section 4.4,0 ParasethesiaImage: Section 4.4,0 ParasethesiaFye disordersImage: Section 4.4,0 ParasethesiaImage: Section 4.4,0 ParasethesiaImage: Section 4.4,0 ParasethesiaFye disordersImage: Section 4.4,0 ParasethesiaImage: Section 4.4,0 ParasethesiaImage: Section 4.4,0 ParasethesiaFye disordersImage: Section 4.4,0 ParasethesiaImage: Section 4.4,0 <b< td=""><td></td><td></td><td>state</td><td>e.g.</td><td>self-</td></b<>			state	e.g.	self-
Person Adjtation Abnormal dreamsbehaviour including Agitation Abnormal dreamsbehaviour including Agitation or suicidal attempt (see section 4.4)Nervous system disordersHeadache DizzinessSomnolence Tremor DysgeusiaConvulsions (see section 4.3) and 4.4) Peripheral sensory motor neuropathy (see ParasethesiaPeripheral sensory motor neuropathy (see section 4.4)Image: section and 4.4)Headache DizzinessSomnolence Tremor DysgeusiaConvulsions section 4.3 and 4.4) Peripheral sensory motor neuropathy (see section 4.4)Image: section and 4.4)Hearing loss Harosmia intracranial hypertension HypoaesthesiaImage: section adisordersImage: section 4.4)Hearing loss Hearing immairedImage: section adisordersImage: section adisorders<			Nervousness	hallucinations	endangering
Depression Agitation Agitation dreams Nightmaresincluding suicidal ideation or suicide attempt (see section 4.4)Nervous system disordersHeadache DizzinessSomnolence Tremor DysgeusiaConvulsions (see section 4.3) and 4.4) neuropathy (see section 4.4)Peripheral sensory section section 4.4) Peripheral sensory motor neuropathy (see section 4.4)Revous disordersHeadache DizzinessSomnolence Tremor DysgeusiaConvulsions (see section 4.3) and 4.4) Peripheral sensory motor neuropathy (see section 4.4) ParasethesiaPeripheral sensory motor neuropathy (see section 4.4) Parosmia includingLabyrinth disordersImage: Section 4.4)Addition and a section section 4.4)Addition and a section section 4.4)Ear and Labyrinth disordersVertigoTinnitusHearing loss Hearing impaired				, paranoia)	behaviour
Agitation Abnormal dreams Nightmaressuicidal ideation or suicide attempt (see section 4.4)Nervous system disordersHeadache DizzinessSomnolence Tremor DysgeusiaConvulsions (see section 4.3 and 4.4)Peripheral sensory section 4.4)Nervous system disordersHeadache DizzinessSomnolence Tremor DysgeusiaConvulsions (see ParasethesiaPeripheral sensory motor neuropathy (see section 4.4)Parosmia including anosmia Dyskinesia Extrapyramida 1and 4.4) Peripheral sensory motor (see ParasethesiaAgitation termor section 4.3 and 4.4)Peripheral sensory motor neuropathy (see Parasethesiaanosmia Dyskinesia Extrapyramida 1 disorder Ageusia Synocope Benign intracranial hypertension HypoaesthesiaFye disordersImage: Section 4.4)Image: Section 4.4)Ear and Labyrithd disordersVertigoTinnitusHearing loss Hearing impaired				Depression	including
Nervous system disordersHeadache DizzinessSomnolence Tremor DysgeusiaConvulsions (see section 4.3 and 4.4) Peripheral sensory section 4.4)Peripheral sensory section neuropathy (see ParasethesiaImage: Construct disordersImage: Construct Peripheral sensory motor neuropathy (see ParasethesiaConvulsions (see section 4.3 and 4.4) Peripheral sensory motor neuropathy (see section 4.4)Image: Construct ParasethesiaImage: Con				Agitation	suicidal
Nervous system disordersHeadache DizzinessSomnolence Tremor DysgeusiaConvulsions (see section 4.3 and 4.4) Peripheral sestor 4.4)Peripheral sensory section section 4.4) Peripheral sensory motor neuropathy (see se section 4.4)Nervous disordersHeadache DizzinessSomnolence Tremor DysgeusiaConvulsions section 4.3 and 4.4) Peripheral sensory motor neuropathy (see section 4.4) Parosmia including anosmia Dyskinesia Extrapyramida 1 disordersEye disordersImage: Section 4.3 A.4)Autor Peripheral sensory motor neuropathy (see section 4.4) Parosmia including anosmia Dyskinesia Extrapyramida 1 disorder Ageusia Synocope Benign intracranial hypertension HypoaesthesiaEye disordersImage: Section 4.4 Parosmia includingImage: Section 4.4 Parosmia including anosmia Dyskinesia Extrapyramida 1 disorder Ageusia Synocope Benign intracranial hypertension HypoaesthesiaEar and Labyrinth disordersVertigoTinnitusHearing loss Hearing impaired				Abnormal	ideation or
Nervous system disordersHeadache DizzinessSomnolence Tremor DysgeusiaConvulsions (see section 4.3 and 4.4) Peripheral sensory section 4.4)Peripheral sensory section 4.4) Peripheral sensory motor neuropathy (see ParasethesiaSomotor neuropathy (see section 4.4)Image: Some section 4.3 and 4.4) Peripheral section 4.3 and 4.4)Peripheral sensory motor neuropathy (see ParasethesiaSomotor neuropathy (see section 4.4)Image: Some section 4.3 and 4.4) Parosenia includingAdditional and 4.4) Parosenia includingPeripheral sensory motor neuropathy (see section 4.4)Image: Some section 4.3 and 4.4)Peripheral sensory motor neuropathy (see section 4.4)Peripheral sensory motor neuropathy (see section 4.4)Image: Some section 4.3 and 4.4)Peripheral sensory motor neuropathy (see section 4.4)Peripheral sensory motor neuropathy (see section 4.4)Image: Some section 4.3 and 4.4)Peripheral sensory motor neuropathy (see section 4.4)Peripheral sensory motor neuropathy (see section 4.4)Image: Some section 4 4.4)Peripheral section 4.4)Peripheral section 4.4)Image: Some section 4 4.4)Peripheral section 4.4)Peripheral section 4.4)Image: Some section 4 4.4)Peripheral section 4.4)Peripheral section 4.4)Image: Some section 4 4.4)Peripheral section 4.4)Peripheral section 4.4)Image: Some s				dreama	anioida
Nervous system disordersHeadache DizzinessSomnolence Tremor DysgeusiaConvulsions (see and 4.4) neuropathy (see ParasethesiaPeripheral sensory section 4.4) Peripheral sensory motor neuropathy (see section 4.4)APeripheral sensory motor neuropathy (see section 4.4)Sensory motor neuropathy (see section 4.4)ParasethesiaParosmia includingEye disordersImage: Section 4.3 ParasethesiaSomolence section 4.3 and 4.4) Parosmia includingEye disordersImage: Section 4.3 Parosmia ParasethesiaSomolence section 4.3 and 4.4) Parosmia Dyskinesia Extrapyramida I disorder Ageusia Synocope Benign intracranial hypertension HypoaesthesiaEye disordersImage: Section A.4)Image: Section A.4)Ear and LabyrinthVertigoTinnitusHearing loss Hearing impaired				dreams	suicide
Nervous system disordersHeadache DizzinessSomnolence Tremor DysgeusiaConvulsions (see section 4.3) and 4.4) Peripheral sensory section 4.4)Peripheral sensory motor neuropathy (see ParasethesiaImage: Control of the system disordersImage: Control of the system DysgeusiaImage: Control of the system section 4.3 and 4.4) Peripheral sensory motor neuropathy (see ParasethesiaImage: Control of the system sensory section 4.4)Image: Control of the system disordersImage: Control of the system disordersImage: Control of the system sensory sectionImage: Control of the system disordersImage: Control of the system disordersImage: Control of the system disordersImage: Control of the system disordersImage: Control of the system disorderImage: Control of the system disordersImage: Control of the system disorder systemImage: Control of the system disorder disorderImage: Control of the system disorder disorderImage: Control of the system disordersImage: Control of the system disorderImage: Control of the system disorderImage: Control of the system disorderImage: Control of the system disordersImage: Control of the system disorderImage: Control of the system disorderImage: Control of the system disorderImage: Control of the system disordersImage: Control of the system disorderImage: Control of the system disorderImage: Control of the systemImage: Control of the systemImage: Control of the system disorderImage: Control of the system<				Nightmares	attempt (see
Nervous system disordersHeadache DizzinessSomnolence TremorConvulsions (see and 4.4) neuropathy (see ParasethesiaPeripheral sensory motor neuropathy (see section 4.4)and 4.4) neuropathy (see ParasethesiaPeripheral sensory motor neuropathy (see section 4.4)Peripheral sensory motor neuropathy (see section 4.4)and 5.4) parasethesiaPeripheral sensory motor neuropathy (see section 4.4)Peripheral sensory motor neuropathy (see section 4.4)and 5.4) parasethesiaParasethesiaParaosmia includinganos mai includingIncludingParaosmia includinganos parasethesiaParasethesiaDyskinesia Extrapyramida 1 disorder Ageusia Synocope Benign intracranial hypetension HypoaesthesiaEye disordersPeripheral section 4.4)Ioss (see section 4.4)Ear and LabyrinthVertigoTinnitusHearing loss Hearing immaired					section 4.4)
system disordersDizzinessTremor Dysgeusia(see section 4.3 and 4.4)sensory section 4.4)and 4.4) neuropathy (see ParasethesiaPeripheral sensory motor neuropathy (see section 4.4)Peripheral sensory motor neuropathy (see section 4.4)and 5.4) ParasethesiaParasethesiaIncluding anosmia Dyskinesia Extrapyramida 1and 5.4) ParasethesiaParasethesiaIncluding anosmia Dyskinesia Extrapyramida 1anos disordersParasethesiaParasethesia ParasethesiaDyskinesia Extrapyramida 1Ear and Labyrinth disordersVertigoVisual disordersJoss (see section 4.4)Ear and LabyrinthVertigoTinnitusHearing loss Hearing	Nervous	Headache	Somnolence	Convulsions	Peripheral
disordersDysgeusiasection 4.3 and 4.4)4.4)Peripheral sensory motor neuropathy (see Parasethesiasensory motor neuropathy (see section 4.4)Parosmia including4.4)Parosmia includingImage: Section 4.3 and 4.4) reuropathy (see parasethesiaand 4.4) reuropathy (see section 4.4)Parosmia includingImage: Section 4.3 and 4.4) reuropathy (see parasethesiaanosmia Dyskinesia Extrapyramida 1 disorder Ageusia Synocope Benign intracranial hypertension HypoaesthesiaEye disordersVisual disturbances Transient vision such as blurred vision (see section 4.4)Ear and Labyrinth disordersVertigoTinnitusHearing loss HearingVertigo	system	Dizziness	Tremor	(see	sensory section
Eve disorders Eye disorders Ear and Labyrinth Caracters Construction C	disorders		Dysgeusia	section 4.3	4 4)
And 4.7) neuropathy (see ParasethesiaInterpreta sensory motor neuropathy (see section 4.4) Parosmia includingImage: Section of the section of the section anosmiaAnd 4.4) Parosmia including anosmia Dyskinesia Extrapyramida 1 disorder Ageusia Synocope Benign intracranial hypertension HypoaesthesiaEye disordersVisual disordersIoss (see section 4.4)Ear and Labyrinth disordersVertigoTinnitusHearing disordersVertigoTinnitus	alboracro		Dyogouoia	and $(4, 4)$	Perinheral
EveVisualVisualSectiondisorders				and T.T.	a cripiiciai
Seeneturopathy (see section 4.4) ParasethesiaImage: Parasethesia(see section 4.4) Parosmia includingImage: ParasethesiaImage: Parasethesia includingImage: ParasethesiaImage: Parasethesia Image: ParasethesiaImage: ParasethesiaImage: Parasethesia Image: ParasethesiaImage: ParasethesiaImage: Parasethesia Parosmia includingImage: ParasethesiaImage: Parasethesia Image: ParasethesiaImage: ParasethesiaImage: Parasethesia Parosmia includingImage: ParasethesiaImage: Parasethesia Parosmia includingImage: ParasethesiaImage: Parasethesia Parosmia includingImage: ParasethesiaImage: Parasethesia Parosmia Parosmia Image: ParasethesiaImage: ParasethesiaImage: Parasethesia Parosmia Parosmia Image: ParasethesiaImage: ParasethesiaImage: Parasethesia Parosmia Parosmia Image: ParasethesiaImage: ParasethesiaImage: Parasethesia Parosmia 				neuropatity	sensory motor
Parasethesia(see section 4.4)ParosmiaincludingincludinganosmiaDyskinesiaExtrapyramidaLabyrinthIKaranda <td></td> <td></td> <td></td> <td>(see</td> <td>neuropathy</td>				(see	neuropathy
Eye disordersVertigoVisual disturbances Transient vision such as blurred Vertigoloss (see section 4.4)Ear and Labyrinth disordersVertigoTinnitusHearing loss Hearing imraited				Parasethesia	(see section
Eye disordersVertigoVisual disurbances section 4.4)Normal including anosmia Dyskinesia Extrapyramida 1 disorder Ageusia Synocope Benign intracranial hypertension HypoaesthesiaEye disordersVisual disturbances Transient vision such as blurred vision (see section 4.4)Ioss (see section 4.4)Ear and Labyrinth disordersVertigoTinnitusHearing loss Hearing imnaired					4.4)
Image: sectionImage: sectionImage: sectionEar andLabyrinthVertigoTinnitusHearing lossLabyrinthVertigoTinnitusHearing loss					Parosmia
Eye disordersVisual anos builtanosmia Dyskinesia Extrapyramida 1 					including
Eye disordersVisual alisturbances Transient vision such as blurred vision (see section 4.4)Interimentation Dyskinesia Extrapyramida 1 disorder Ageusia Synocope Benign intracranial hypertension HypoaesthesiaEye disordersVisual disturbances Transient vision such as blurred vision (see section 4.4)Ioss (see section 4.4)Ear and Labyrinth disordersVertigoTinnitusHearing loss Hearing imnaired					anosmia
Eye disordersVisual a aIoss (see section 4.4)Ear and Labyrinth disordersVertigoTinnitusHearing disordersVertigoTinnitus					Drustringasia
ExtrapyramidaImage: strapyramidaImage: strapyramidaI					Dyskinesia
Eye disordersI disorder Ageusia Synocope Benign intracranial hypertension HypoaesthesiaEye disordersVisual disturbances Transient vision such as blurred vision (see section 4.4)loss (see section 4.4)Ear and Labyrinth disordersVertigoTinnitusHearing loss Hearing impaired					Extrapyramida
LabyrinthVertigoKisorderLabyrinthVertigoTinnitusHearing lossLabyrinthVertigoTinnitusHearing loss					1
Eye disordersAgeusia Synocope Benign intracranial hypertension HypoaesthesiaEye disordersVisual disturbances Transient vision such as blurred vision (see section 4.4)loss (see section 4.4)Ear and Labyrinth disordersVertigoTinnitusHearing loss Hearing impaired					disorder
Eye disordersVisual a aIoss (see section 4.4)Ear and Labyrinth disordersVertigoTinnitusEar and LabyrinthVertigoTinnitusHearing impairedVertigoTinnitus					Ageusia
Eye disordersVisual and and burnedloss (see section 4.4)Ear and Labyrinth disordersVertigoTinnitusEar and LabyrinthVertigoTinnitusHearing impairedIntrospic Benign intracranial hypertension Hypoaesthesia					Synocope
Eye disordersVisual a aloss (see section tabured vision such as blurred vision (see section 4.4)Ear and Labyrinth disordersVertigoTinnitusHearing loss Hearing impaired					Renign
Eye disordersVisual adisturbances Transient vision such as blurred vision (see section 4.4)Ioss (see section 4.4)Ear and Labyrinth disordersVertigoTinnitusHearing loss Hearing impaired					intro orogial
Eye disordersVisual adisturbancesloss (see sectionEye disordersVisual disturbancesloss (see sectionTransient vision such as blurred vision (see section 4.4)4.4)Ear and Labyrinth disordersVertigoTinnitusHearing impairedHearing impaired					intracramat
Eye disordersVisual disturbancesloss (see sectionEye disordersVisual disturbancesloss (see sectionTransient vision such as blurred vision (see section 4.4)4.4)Ear and Labyrinth disordersVertigoTinnitusHearing impairedHearing impaired					nypertension
Eye disordersVisual loss (see sectiondisordersVisual disturbances Transient vision such as blurred vision (see section 4.4)loss (see section 4.4)Ear and Labyrinth disordersVertigoTinnitusHearing loss Hearing impaired					Hypoaesthesia
disordersdisturbancessectiondisordersTransient4.4)vision such as blurred vision (see section 4.4)4.4)Ear and Labyrinth disordersVertigoTinnitusHearing impairedHearing impaired	Eye			Visual	loss (see
Ear and Labyrinth disordersVertigoTransient vision such as blurred vision (see section 4.4)4.4)Ear and Labyrinth disordersVertigoTinnitusHearing loss impaired	disorders			disturbances	section
Ear and Labyrinth disordersVertigoTinnitusHearing loss Hearing impaired				Transient	4.4)
Vision stell as blurred vision (see section 4.4)Ear and Labyrinth disordersVertigoTinnitusHearing loss Hearing impaired				vision such as	,
Ear and Vertigo Tinnitus Hearing loss Labyrinth Hearing impaired				hurrod	
Ear and Vertigo Vision (see section 4.4) Labyrinth Vertigo Tinnitus disorders Imagined					
section 4.4)Ear and Labyrinth disordersVertigoTinnitusHearing loss Hearing impaired				vision (see	
Ear and Labyrinth disordersVertigo4.4)Hearing loss Hearing impaired				section	
Ear and Labyrinth disordersVertigoTinnitusHearing lossHearing impaired				4.4)	
Labyrinth Hearing impaired	Ear and		Vertigo	Tinnitus	Hearing loss
disorders	Labvrinth		6-		Hearing
	disorders				impaired

Cardiac			Tachycardia	Ventricular
disorders			Palpitation	tachycardia,
			1	which may
				result in
				cardiac arrest
				Venticular
				arrhythmia
				and
				torsade de
				pointes
				(reported
				predominantly
				in
				natients with
				risk
				factors of OT
				prolongation)
				electrocardiogr
				am
				OT prolonged
				(see sections
				4.4 and
				4.9)
Vascular	Applies to		Hypotension	
disorders	i.v. form		51	
	only:			
	Phlebitis			
Respiratory,		Dyspnoea		Bronchospasm
thoracic		51		Pneumonitis
and				
medistinal				
disorders				allergic
Gastro-	Diarrhoea	Abdominal		Diarrhoea -
intestinal	Vomiting	pain		haemorrhagic
disorders	Nausea	Dyspepsia		which in very
		Flatulence		rare cases may
		Constipation		be indicative of
		-		enterocolitis,
				including
				pseudomembr
				anous colitis
				(see section
				4.4)
				Pancreatitis
Hepatobiliar	Hepatic	Blood bilirubin		Jaundice and
y disorders	enzyme	increased		severe liver
	increased			injury,
	(ALT/AST,			including
	alkaline			cases with
	phosphatas			fatal acute liver
	e, CGT)			failure,
	. ,			primarily with
				severe
				underlying
				diseases (see
				section 4.4)
				Hepatitis

Skin and		Rash		Toxic
subcutaneo		Pruritus		epidermal
us tissue		Urticaria		necrolysis
disorders		Hyperhidrosis		Stevens-
				Johnson
				syndrome
				Erythema
				multiforme
				Photosensitivit
				y reaction (see
				section 4.4)
				Leukocytoclast
				ic
				vasculitis
				Stomatitis
Musculoske		Arthralgia	Tendon	Rhabdomyolysi
letal and		Myalgia	disorders (see	S
connective			sections 4.3	Tendon
tissue			and 4.4)	rupture (e.g.
disorders			including	Achilles
			tendinitis (e.g.	tendon) (see
			Achilles	sections 4.3
			tendon)	and
			Muscle	4.4)
			weakness	Ligament
			which may be	rupture
			of special	Muscle rupture
			importance in	Arthritis
			patients with	
			myasthenia	
			gravis (see	
			section 4.4)	
Renal and		Blood	Renal failure	
Urinary		creatinine	acute (e.g. due	
disorders		increased	to interstitial	
			nephritis)	
General	Applies to		Pyrexia	Pain (including
disorders	i.v. form			pain in back,
and	Asthenia			chest, and
administrati	only:			extremities)
on site	Infusion			
conditions	site reaction			
	(pain,			
	reddening)			

Amoxicillin

As with other penicillin, it may be expected that untoward reactions will be essentially limited to sensitivity phenomena. They are more likely to occur in individuals who have previously demonstrated hypersensitivity to penicillin and in those with a history of allergy, asthma, hay fever or uetica. The following adverse reactions have been reported as associated with the use of penicillin.

Gastrointestinal: Glossitis, stomatits, nausea, vomiting, diarrhea, entero- colis and pseudomembranous colitis. These reactions are usually associated with oral dosage forms of the drug.

Hypersensitivity: Occurrence of an erythematous, midly pruritic; maculopapular skin rash has been reported.

4.9 Overdose

Esomeprazole

There is very limited experience to date with deliberate overdose. The symptoms described in connection with 280 mg were gastrointestinal symptoms and weakness. Single doses of 80 mg Esomeprazole were uneventful. No specific antidote is known. Esomeprazole is extensively plasma protein bound and is therefore not readily dialyzable. As in any case of overdose, treatment should be symptomatic and general supportive measures should be utilised.

Levofloxacin

According to toxicity studies in animals or clinical pharmacology studies performed with supra- therapeutic doses, the most important signs to be expected following acute overdose of levofloxacin tablets are central nervous symptoms such as confusion, dizziness, impairment of consciousness, and convulsive seizures, increases in QT interval as well as gastro-intestinal reactions such as nausea and mucosal erosions.

CNS effects include confusional state, convulsion, hallucination, and tremor have been observed in post marketing experience.

In the event of overdose, symptomatic treatment should be implemented. ECG monitoring should be undertaken, because of the possibility of QT interval prolongation. Antacids may be used for protection of gastric mucosa. Haemodialysis, including peritoneal dialysis and CAPD, are not effective in removing levofloxacin from the body.

No specific antidote exists.

Amoxicillin

Gastrointestinal effects such as nausea, vomiting and diarrhoea may be evident and should be treated symptomatically with attention to the water/electrolyte balance. Amoxicillin crystalluria, in some cases leading to renal failure, has been observed.

Amoxicillin may be removed from the circulation by haemodialysis.

5. Pharmacological properties

5.1 Pharmacodynamic properties

Esomeprazole

Pharmacotherapeutic group: Drugs for acid-related disorders proton pump inhibitors

ATC Code: A02B C05

Esomeprazole is the S-isomer of omeprazole and reduces gastric acid secretion through a specific targeted mechanism of action. It is a specific inhibitor of the acid pump in the parietal cell. Both the R- and S-isomer of omeprazole have similar Pharmacodynamic activity.

Mechanism of action

Esomeprazole is a weak base and is concentrated and converted to the active form in the highly acidic environment of the secretory canaliculi of the parietal cell, where it inhibits the enzyme H+K+ -ATPase – the acid pump and inhibits both basal and stimulated acid secretion.

Pharmacodynamic effects

After oral dosing with Esomeprazole 20 mg and 40 mg the onset of effect occurs within one hour. After repeated administration with 20 mg Esomeprazole once daily for five days, mean peak acid output after pentagastrin stimulation is decreased 90% when measured 6–7 hours after dosing on day five.

After five days of oral dosing with 20 mg and 40 mg of Esomeprazole, intragastric pH above 4 was maintained for a mean time of 13 hours and 17 hours, respectively over 24 hours in symptomatic GERD

patients. The proportion of patients maintaining an intragastric pH above 4 for at least 8, 12 and 16 hours respectively were for Esomeprazole 20 mg 76%, 54% and 24%. Corresponding proportions for Esomeprazole 40 mg were 97%, 92% and 56%.

Using AUC as a surrogate parameter for plasma concentration, a relationship between inhibition of acid secretion and exposure has been shown. Healing of reflux esophagitis with Esomeprazole 40 mg occurs in approximately 78% of patients after four weeks, and in 93% after eight weeks.

One week treatment with Esomeprazole 20 mg b.i.d. and appropriate antibiotics, results in successful eradication of H. pylori in approximately 90% of patients.

After eradication treatment for one week, there is no need for subsequent monotherapy with antisecretory drugs for effective ulcer healing and symptom resolution in uncomplicated duodenal ulcers.

Levofloxacin

Pharmacotherapeutic group: ATC code: Quinolone antibacterials - Fluoroquinolones J01MA12 Levofloxacin is a synthetic antibacterial agent of the fluoroquinolone class and is the S(-) enantiomer of the racemic drug substance ofloxacin.

Mechanism of action

As a fluoroquinolone antibacterial agent, levofloxacin acts on the DNA-DNA-gyrase complex and topoisomerase IV.

PK/PD relationship

The degree of the bactericidal activity of levofloxacin depends on the ratio of the maximum concentration in serum (Cmax) or the area under the curve (AUC) and the minimal inhibitory concentration (MIC).

Mechanism of resistance

Resistance to levofloxacin is acquired through a stepwise process by target site mutations in both type II topoisomerases, DNA gyrase and topoisomerase IV. Other resistance mechanisms such as permeation barriers (common Pseudomonas aeruginosa) and efflux mechanisms may affect susceptibility to levofloxacin.

Cross-resistance between levofloxacin and other fluoroquinolones is observed. Due to the mechanism of action, there is generally no crossresistance between levofloxacin and other classes of antibacterial agents.

Amoxicillin

Mechanisms of Action/Effect

Amoxicillin is similar to penicillin in its bactericidal action against susceptible bacteria during the stage of active multiplication. It acts through the inhibition of cell wall biosynthesis that leads to the death of the bacteria.

Amoxicillin is bactericidal. Like all penicillins it acts by interfering with the synthesis of the cell wall of the bacterium.

Amoxicillin is inactivated by penicillinase. Penicillinase-producing strains of Staphylococcus aureus and Gram-negative organisms (e.g. Escherichia coli, Proteus, Klebsiella) are resistant.

Complete cross-resistance occurs with ampicillin and amoxicillin.

5.2 Pharmacokinetic properties

Esomeprazole

Absorption

Esomeprazole is acid labile and is administered orally as enteric-coated granules. In vivo conversion to the R-isomer is negligible. Absorption of Esomeprazole is rapid, with peak plasma levels occurring approximately 1-2 hours after dose. The absolute bioavailability is 64% after a single dose of 40 mg and increases to 89% after repeated once daily administration. For 20 mg Esomeprazole the corresponding values are 50% and 68% respectively.

Food intake both delays and decreases the absorption of Esomeprazole although this has no significant influence on the effect of Esomeprazole on intragastric acidity.

Distribution

The apparent volume of distribution at steady state in healthy subjects is approximately 0.22 l/kg body weight. Esomeprazole is 97% plasma protein bound.

Biotransformation

Esomeprazole is completely metabolised by the cytochrome P450 system (CYP). The major part of the metabolism of Esomeprazole is dependent on the polymorphic CYP2C19, responsible for the formation of the hydroxy- and desmethyl metabolites of Esomeprazole. The remaining part is dependent on another specific isoform, CYP3A4, responsible for the formation of Esomeprazole sulphone, the main metabolite in plasma.

Elimination

The parameters below reflect mainly the pharmacokinetics in individuals with a functional CYP2C19 enzyme, extensive metabolisers.

Total plasma clearance is about 17 l/h after a single dose and about 9 l/h after repeated administration.

The plasma elimination half-life is about 1.3 hours after repeated once daily dosing. Esomeprazole is completely eliminated from plasma between doses with no tendency for accumulation during once-daily administration.

The major metabolites of Esomeprazole have no effect on gastric acid secretion. Almost 80% of an oral dose of Esomeprazole is excreted as metabolites in the urine, the remainder in the faeces. Less than 1% of the parent drug is found in urine.

Linearity/non-linearity

The pharmacokinetics of Esomeprazole has been studied in doses up to 40 mg twice daily The area under the plasma concentration-time curve increases with repeated administration of Esomeprazole. This increase is dose-dependent and results in a more than dose proportional increase in AUC after repeated administration. This time- and dose-dependency is due to a decrease of first pass metabolism and systemic clearance probably caused by an inhibition of the CYP2C19 enzyme by Esomeprazole and/or its sulphone metabolite.

Special patient populations

Poor metabolisers

Approximately 2.9 \pm 1.5% of the population lack a functional CYP2C19 enzyme and are called poor metabolisers. In these individuals the metabolism of Esomeprazole is probably mainly catalysed by CYP3A4. After repeated once daily administration of 40 mg Esomeprazole, the mean area under the plasma concentration-time curve was approximately 100% higher in poor metabolisers than in subjects having a functional CYP2C19 enzyme (extensive metabolisers). Mean peak plasma concentrations were increased by about 60%. These findings have no implications for the posology of Esomeprazole.

<u>Gender</u>

Following a single dose of 40 mg Esomeprazole the mean area under the plasma concentration-time curve is approximately 30% higher in females than in males. No gender difference is seen after repeated once daily administration. These findings have no implications for the posology of Esomeprazole.

<u>Hepatic impairment</u>

The metabolism of Esomeprazole in patients with mild to moderate liver dysfunction may be impaired. The metabolic rate is decreased in patients with severe liver dysfunction resulting in a doubling of the area under the plasma concentration-time curve of Esomeprazole. Therefore, a maximum of 20 mg should not be exceeded in patients with severe dysfunction. Esomeprazole or its major metabolites do not show any tendency to accumulate with once daily dosing.

<u>Renal impairment</u>

No studies have been performed in patients with decreased renal function. Since the kidney is responsible for the excretion of the metabolites of Esomeprazole but not for the elimination of the parent compound, the metabolism of Esomeprazole is not expected to be changed in patients with impaired renal function.

<u>Older people</u>

The metabolism of Esomeprazole is not significantly changed in elderly subjects (71-80 years of age).

Paediatric population

Adolescents 12-18 years:

Following repeated dose administration of 20 mg and 40 mg Esomeprazole, the total exposure (AUC) and the time to reach maximum plasma drug concentration (tmax) in 12- to 18-year-olds was similar to that in adults for both Esomeprazole doses.

Levofloxacin

Absorption

Orally administered levofloxacin is rapidly and almost completely absorbed with peak plasma concentrations being obtained within 1-2 h. The absolute bioavailability is 99 - 100%.

Food has little effect on the absorption of levofloxacin.

Steady state conditions are reached within 48 hours following a 500 mg once or twice daily dosage

regimen.

Distribution

Approximately 30 – 40% of levofloxacin is bound to serum protein. The mean volume of distribution of levofloxacin is approximately 100 l after single and repeated doses, indicating widespread distribution into body tissues.

Penetration into tissues and body fluids:

Levofloxacin has been shown to penetrate into bronchial mucosa, epithelial lining fluid alveolar macrophages, lung tissue, skin (blister fluid), prostatic tissue and urine. However, levofloxacin has poor penetration intro cerebro-spinal fluid.

Biotransformation

Levofloxacin is metabolised to a very small extent, the metabolites being desmethyl-levofloxacin and levofloxacin N-oxide. These metabolites account for < 5% of the dose excreted in urine. Levofloxacin is stereochemically stable and does not undergo chiral inversion.

Elimination

Following oral and intravenous administration of levofloxacin, it is eliminated relatively slowly from the plasma ($t\frac{1}{2}$: 6 – 8 h). Excretion is primarily by the renal route (>85% of the administered dose).

The mean apparent total body clearance of levofloxacin following a 500 mg single dose was 175 +/- 29.2 ml/min.

There are no major differences in the pharmacokinetics of levofloxacin following intravenous and oral administration, suggesting that the oral and intravenous routes are interchangeable.

<u>Linearity</u>

Levofloxacin obeys linear pharmacokinetics over a range of 50 to 1000 mg.

Special populations

Subjects with renal insufficiency

The pharmacokinetics of levofloxacin are affected by renal impairment. With decreasing renal function renal elimination and clearance are decreased, and elimination half-lives increased as shown in the table below:

Pharmacokinetics in renal insufficiency following single oral 500 m dose

Cl _{cr} [ml/min]	<20	20 - 49	50-80	
Cl _R [ml/min]	13	26	57	
$T_{1/2}[h]$	35	27	9	
D11 1 1 1				

Elderly subjects

There are no significant differences in levofloxacin kinetics between young and elderly subjects, except those associated with differences in creatinine clearance.

Gender differences

Separate analysis for male and female subjects showed a small to marginal gender differences in levofloxacin pharmacokinetics. There is no evidence that these gender differences are of clinical relevance.

Amoxicillin

Amoxicillin is stable in the acid gastric secretion and is rapidly absorbed from the gastrointestinal tract after oral administration. The presence of food does not interfere with this process. Peak plasma concentrations are obtained in about two hours, producing around 2.5 times the peak concentration resulting from comparable doses of ampicillin.

Protein binding is similar to that of ampicillin: up to 25%. Effective levels in the cerebrospinal fluid are obtained only in the presence of inflammation and then irregularly. About 60% of an orally administered dose is excreted unchanged in the urine. It penetrates

well in to purulent and mucoid sputum.

In preterm infants with gestational age 26-33 weeks, the total body clearance after intravenous dosing of amoxicillin, day 3 of life, ranged between 0.75 - 2 ml/min, very similar to the inuline clearance (GFR) in this population. Following oral administration, the absorption pattern and the bioavailability of amoxicillin in small children may be different to that of adults. Consequently, due to the decreased CL, the exposure is expected to be elevated in this group of patients, although this increase in exposure may in part be diminished by decreased bioavailability when given orally

5.3 Preclinical safety data

Esomeprazole

Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeated dose toxicity, genotoxicity, carcinogenic potential, toxicity to reproduction and development. Adverse reactions not observed in clinical studies, but seen in animals at exposure levels similar to clinical exposure levels and with possible relevance to clinical use were as follows:

Carcinogenicity studies in the rat with the racemic mixture have shown gastric ECL-cell hyperplasia and carcinoids. These gastric effects in the rat are the result of sustained, pronounced hypergastrinaemia secondary to reduced production of gastric acid and are observed after long-term treatment in the rat with inhibitors of gastric acid secretion.

Non-clinical data reveal no special hazard based on conventional studies of single dose toxicity, repeated dose toxicity, carcinogenic potential and toxicity to reproduction and development.

Levofloxacin

Levofloxacin caused no impairment of fertility or reproductive performance in rats and its only effect on foetuses was delayed maturation as a result of maternal toxicity.

Levofloxacin did not induce gene mutations in bacterial or mammalian cells but did induce chromosome aberrations in Chinese hamster cells in vitro. These effects can be attributed to inhibition of topoisomerase II. In vivo tests (micronucleus, sister chromatid exchange, unscheduled DNA synthesis, dominant lethal tests) did not show any genotoxic potential.

Studies in the mouse showed levofloxacin to have phototoxic activity only at very high doses.

Levofloxacin did not show any genotoxic potential in a photo mutagenicity assay, and it reduced tumour development in a photo carcinogenicity study.

In common with other fluoroquinolones, levofloxacin showed effects on cartilage (blistering and cavities) in rats and dogs. These findings were more marked in young animals.

6. Pharmaceutical particulars

6.1 List of excipients

Esomeprazole

Light Magnesium oxide Mannitol –H Microcrystalline cellulose Maize starch Lactose Povidone Iso –propyl alcohol Purified Talc Magnesium Stearate Colloidal Anhydrous silica Crosscarmelose sodium Titanium dioxide Color Iron oxide yellow Methylene Dichloride

Levofloxacin

Maize Starch Microcrystalline cellulose Lactose Maize Starch Povidone Purified water Purified Talc Magnesium Stearate Sodium Starch Glycolate Colloidal Anhydrous Silica Isopropyl alcohol Titanium dioxide Sunset yellow Methylene Chloride

HPMC E15

Amoxicillin

HPMC E 15 P.V.P K-30 Sodium Starch Glycolate Magnesium Stearate Purified Talc Isopropyl Alcohol Methylene Chloride Titanium dioxide Red oxide of Iron

6.2 Incompatibilities Not applicable

6.3 Shelf life 24 Months

6.4 Special precautions for storage: Store below 30°C Protect from moisture.

6.5 Nature and contents of container

Alu -Alu strip pack. 2 levofloxacin tablets USP 500 mg 2 amoxicillin tablets BP 1000 mg 2 esomeprazole tablets 40 mg In a baby carton with a package insert and 7 such packs in a mono carton.

6.6 Special precautions for disposal and other handling: Dispose as per the local regulatory requirements.

7. Marketing authorization holder and manufacturing site addresses

Marketing authorization holder: PHARMAKEN LTD. Address: P.O Box 95625-80106 Nairobi, Kenya

Manufacturing site address: GLOBAL PHARMA HEALTHCARE Address: A-9, SIDCO PHARMACEUTICAL COMPLEX, Alathur, Thiruporur- 603110. CHENNAI, INDIA.

- 8. Marketing authorization number CTD9365
- 9. Date of first registration

29/06/2022

- **10.** Date of revision of the text: 17/09/2023
- **11. Dosimetry:** Not Applicable

12. Instructions for Preparation of Radiopharmaceuticals: Not Applicable